Dosimetric advantages of proton beam therapy compared to intensity-modulated radiation therapy for retroperitoneal chordoma

by Nathan Y Yu, Sujay A Vora
Published 2019-09-01

Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A...

by Ronik S. Bhangoo, MD, Todd A. DeWees, PhD, Nathan Y. Yu, MD, Julia X. Ding, BA, Chenbin Liu, PhD, Michael A. Golafshar, MS, William G. Rule, MD, Sujay A. Vora, MD, Helen J. Ross, MD, Daniel H. Ahn, DO, Staci E. Beamer, MD, Dawn E. Jaroszewski, MD, Christopher L. Hallemeier, MD, Wei Liu, PhD, Jonathan B. Ashman, MD, PhD, Terence T. Sio, MD, MS
Published 2020-09-01

Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non–Small Cell Lung Cancer: The Mayo Clinic Experience

by Corey J. Hobbs, MD, Stephen J. Ko, MD, Nitesh N. Paryani, MD, Joseph M. Accurso, MD, Kenneth R. Olivier, MD, Yolanda I. Garces, MD, Sean S. Park, MD, MS, PhD, Christopher L. Hallemeier, MD, Steven E. Schild, MD, Sujay A. Vora, MD, Jonathan B. Ashman, MD, PhD, William G. Rule, MD, Johnny R. Bowers, BS, Michael G. Heckman, MS, Nancy N. Diehl, MBA, Robert C. Miller, MD
Published 2018-03-01